Resveratrol inhibits Epstein Barr Virus lytic cycle in Burkitt's lymphoma cells by affecting multiple molecular targets

Antiviral Research

Volumn 96, Issue 2, 2012, Pages 196-202

  De Leo, Alessandra ^a   Arena, Giuseppe ^a,b   Lacanna, Egidio ^a   Oliviero, Giorgio ^a   Colavita, Francesca ^a   Mattia, Elena ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Epstein Barr Virus; Lytic infection; Protein synthesis; Resveratrol; ROS; Transcription factors

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1;

ANTIVIRAL ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CELL CYCLE PROGRESSION; DOSE RESPONSE; EPSTEIN BARR VIRUS; GENE EXPRESSION; HEART PROTECTION; IN VITRO STUDY; LIFE CYCLE; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; MONONUCLEOSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRUS ACTIVATION; VIRUS PARTICLE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; HERPESVIRUS 4, HUMAN; HUMANS; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; STILBENES; VIRAL PROTEINS; VIRUS REPLICATION;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4; INFLUENZA A VIRUS; POLYOMAVIRUS;

EID: 84867235241     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.09.003     Document Type: Article

References (43)

1. Amon W., Farrell P.J. Reactivation of Epstein-Barr virus from latency. Rev Med Virol 2005, 15:149-156.
2. Angel P., Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991, 1072:129-157.
3. Berardi V., Ricci F., Castelli M., Galati G., Risuleo G. Resveratrol exhibits a strong cytotoxic activity in cultured cells and has an antiviral action against polyomavirus: potential clinical use. J Exp Clin Cancer Res 2009, 28:96.
4. Bhat K.P.L., Kosmeder J.W., Pezzuto J.M. Biological effects of resveratrol. Antioxid Redox Signal 2001, 3:1041-1064.
5. Borra M.T., Smith B.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005, 280:17187-17195.
6. Campagna M., Rivas C. Antiviral activity of resveratrol. Biochem Soc Trans 2010.
7. Cayrol C., Flemington E.K. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor beta igh3 (TGF-beta igh3) and TGF-beta 1. J Virol 1995, 69:4206-4212.
8. De Leo A., Arena G., Stecca C., Raciti M., Mattia E. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program. Molecular cancer research: MCR 2011, 9:1346-1355.
9. De Paoli P. Epstein-Barr virus: novel patented therapeutics. Expert Opin Ther Pat 2010, 20:807-818.
10. Docherty J.J., Fu M.M., Hah J.M., Sweet T.J., Faith S.A., Booth T. Effect of resveratrol on herpes simplex virus vaginal infection in the mouse. Antiviral Res 2005, 67:155-162.
11. Docherty J.J., Sweet T.J., Bailey E., Faith S.A., Booth T. Resveratrol inhibition of varicella-zoster virus replication in vitro. Antiviral Res 2006, 72:171-177.
12. Dyson O.F., Walker L.R., Whitehouse A., Cook P.P., Akula S.M. Resveratrol inhibits KSHV reactivation by lowering the levels of cellular EGR-1. PLoS ONE 2012, 7:e33364.
13. Evers D.L., Wang X., Huong S.M., Huang D.Y., Huang E.S. 3,4',5-Trihydroxy-trans-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signaling. Antiviral Res 2004, 63:85-95.
14. Faith S.A., Sweet T.J., Bailey E., Booth T., Docherty J.J. Resveratrol suppresses nuclear factor-kappaB in herpes simplex virus infected cells. Antiviral Res 2006, 72:242-251.
15. Gaeta A., Verzaro S., Cristina L.M., Mancini C., Nazzari C. Diagnosis of neurological herpesvirus infections: real time PCR in cerebral spinal fluid analysis. New Microbiol 2009, 32:333-340.
16. Gargouri B., Nasr R., ben Mansour R., Lassoued S., Mseddi M., Attia H., El Feki Ael F., Van Pelt J. Reactive oxygen species production and antioxidant enzyme expression after Epstein-Barr virus lytic cycle induction in Raji cell line. Biol Trace Elem Res 2011, 144:1449-1457.
17. Greenspan J.S., Greenspan D., Lennette E.T., Abrams D.I., Conant M.A., Petersen V., Freese U.K. Replication of Epstein-Barr virus within the epithelial cells of oral " hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med 1985, 313:1564-1571.
18. Hong G.K., Gulley M.L., Feng W.H., Delecluse H.J., Holley-Guthrie E., Kenney S.C. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol 2005, 79:13993-14003.
19. Hsu M., Wu S.-Y., Chang S.-S., Su I.-J., Tsai C.-H., Lai S.-J., Shiau A.-L., Takada K., Chang Y. Epstein-Barr Virus Lytic Transactivator Zta Enhances Chemotactic Activity through Induction of Interleukin-8 in Nasopharyngeal Carcinoma Cells. J Virol 2008, 82:3679-3688.
20. Jones R.J., Seaman W.T., Feng W.H., Barlow E., Dickerson S., Delecluse H.J., Kenney S.C. Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease. Int J Cancer 2007, 121:1274-1281.
21. Kundu J.K., Shin Y.K., Surh Y.J. Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-kappaB and AP-1 as prime targets. Biochem Pharmacol 2006, 72:1506-1515.
22. Kutok J.L., Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 2006, 1:375-404.
23. Lassoued S., Gargouri B., El Feki Ael F., Attia H., Van Pelt J. Transcription of the Epstein-Barr virus lytic cycle activator BZLF-1 during oxidative stress induction. Biol Trace Elem Res 2010, 137:13-22.
24. Lin A., Karin M. NF-kappaB in cancer: a marked target. Semin Cancer Biol 2003, 13:107-114.
25. Ma S.D., Hegde S., Young K.H., Sullivan R., Rajesh D., Zhou Y., Jankowska-Gan E., Burlingham W.J., Sun X., Gulley M.L., Tang W., Gumperz J.E., Kenney S.C. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 2011, 85:165-177.
26. Mahot S., Sergeant A., Drouet E., Gruffat H. A novel function for the Epstein-Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene. J Gen Virol 2003, 84:965-974.
27. Manna S.K., Mukhopadhyay A., Aggarwal B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000, 164:6509-6519.
28. Martin S.J., Lennon S.V., Bonham A.M., Cotter T.G. Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J Immunol 1990, 145:1859-1867.
29. Matusali G., Arena G., De Leo A., Di Renzo L., Mattia E. Inhibition of p38 MAP kinase pathway induces apoptosis and prevents Epstein Barr virus reactivation in Raji cells exposed to lytic cycle inducing compounds. Mol Cancer 2009, 8:18.
30. Miyazaki I., Cheung R.K., Dosch H.M. Viral interleukin 10 is critical for the induction of B cell growth transformation by Epstein-Barr virus. J Exper Med 1993, 178:439-447.
31. Palamara A.T., Nencioni L., Aquilano K., De Chiara G., Hernandez L., Cozzolino F., Ciriolo M.R., Garaci E. Inhibition of influenza A virus replication by resveratrol. J Infect Dis 2005, 191:1719-1729.
32. Ralhan R., Pandey M.K., Aggarwal B.B. Nuclear factor-kappa B links carcinogenic and chemopreventive agents. Front Biosci (Schol Ed) 2009, 1:45-60.
33. Rickinson A.B., Kieff E.B. Epstein Barr Virus 2007, Lippincott Williams & Wilkins, Philadelphia, P.A.
34. Saatian B., Zhao Y., He D., Georas S.N., Watkins T., Spannhake E.W., Natarajan V. Transcriptional regulation of lysophosphatidic acid-induced interleukin-8 expression and secretion by p38 MAPK and JNK in human bronchial epithelial cells. Biochem J 2006, 393:657-668.
35. Shu L., Cheung K.L., Khor T.O., Chen C., Kong A.N. Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis. Cancer Metastasis Rev 2010, 29:483-502.
36. Villa-Cuesta E., Boylan J.M., Tatar M., Gruppuso P.A. Resveratrol Inhibits Protein Translation in Hepatic Cells. PLoS ONE 2011, 6:e29513.
37. Villegas E., Santiago O., Sorlozano A., Gutierrez J. New strategies and patent therapeutics in EBV-associated diseases. Mini Rev Med Chem 2010, 10:914-927.
38. Whitlock N.C., Baek S.J. The anticancer effects of Resveratrol: modulation of transcription factors. Nutr Cancer 2012.
39. Wu F.Y., Wang S.E., Chen H., Wang L., Hayward S.D., Hayward G.S. CCAAT/enhancer binding protein alpha binds to the Epstein-Barr virus (EBV) ZTA protein through oligomeric interactions and contributes to cooperative transcriptional activation of the ZTA promoter through direct binding to the ZII and ZIIIB motifs during induction of the EBV lytic cycle. J Virol 2004, 78:4847-4865.
40. Yiu C.Y., Chen S.Y., Chang L.K., Chiu Y.F., Lin T.P. Inhibitory effects of resveratrol on the Epstein-Barr virus lytic cycle. Molecules 2010, 15:7115-7124.
41. Yu W., Fu Y.C., Wang W. Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem 2012, 113:752-759.
42. Zabel U., Henkel T., Silva M.S., Baeuerle P.A. Nuclear uptake control of NF-kappa B by MAD-3, an I kappa B protein present in the nucleus. Embo J 1993, 12:201-211.
43. Zhang H.-S., Zhou Y., Wu M.-R., Zhou H.-S., Xu F. Resveratrol inhibited Tat-induced HIV-1 LTR transactivation via NAD+-dependent SIRT1 activity. Life Sci 2009, 85:484-489.